Physician profile
Daniel W Kim
NPI 1538218128
$9,364.65
in general payments reported to CMS, 2019-2025
22 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,601 · 2020: $443 · 2021: $270 · 2022: $3,085 · 2023: $1,330 · 2024: $1,384 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043 · Travel and Lodging: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.67 |
| Travel and Lodging | $923.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,433.40 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Medtronic USA, INC. | $1,869.95 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $1,275.63 | 2022 | |
| Relievant Medsystems, INC. | $1,163.51 | 2022-2023 | Intracept |
| Medtronic, INC. | $1,162.80 | 2023-2025 | Intellis Adaptivestim |
| Nalu Medical, INC. | $397.45 | 2022-2024 | Nalu Neurostimulation System |
| Daiichi Sankyo INC. | $352.93 | 2019 | |
| Mml US, INC. | $166.33 | 2024 | Reactiv8 |
| Saol Therapeutics INC. | $104.77 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $99.76 | 2021-2023 | Belbuca, Xtampza |
| Painteq LLC | $79.17 | 2022 | |
| Pfizer INC. | $39.73 | 2019-2025 | |
| Abbvie INC. | $33.15 | 2024 | |
| Saluda Medical Americas, INC. | $32.50 | 2024 | Evoke |
| Radius Health, INC. | $30.08 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $28.99 | 2024 | Qutenza |
| Abbott Laboratories | $21.73 | 2024 | Proclaim |
| Convatec INC. | $18.71 | 2024 | |
| Piramal Critical Care | $15.39 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $15.34 | 2019 | |
| Si-Bone, INC. | $14.95 | 2021 | |
| Vertos Medical, INC. | $8.38 | 2024 | Mild Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.